The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease

11Citations
Citations of this article
17Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Rifampicin is recommended for the treatment of Mycobacterium avium complex pulmonary disease alongside azithromycin and ethambutol. We evaluated the azithromycin-ethambutol backbone with and without rifampicin in an intracellular hollow fiber model and performed RNA sequencing to study the differences in adaptation. In an in vitro hollow fiber experiment, we simulated epithelial lining fluid pharmacokinetic profiles of the recommended 3-drug (rifampicin, ethambutol, and azithromycin) or a 2-drug (ethambutol and azithromycin) treatment. THP-1 cells infected with M. avium ATCC700898 were exposed to these regimens for 21 days. We determined intra- and extra-cellular bacterial load- and THP-1 cell densities on days 0, 3, 7, 14, and 21, alongside RNA sequencing. The emergence of macrolide resistance was studied by inoculating intra- and extra-cellular fractions of azithromycin-containing Middlebrook 7H10 agar plates. Complete pharmacokinetic profiles were determined at days 0 and 21. Both therapies maintained stasis of both intra- and extra-cellular bacterial populations for 3 days, whilst regrowth coinciding with the emergence of a macrolide-resistant subpopulation was seen after 7 days. THP-1 cell density remained static. Similar transcriptional profiles were observed for both therapies that were minimally influenced by exposure duration. Transcriptional response was slightly larger during 2-drug treatment. Rifampicin did not add to the antimycobacterial effect to the 2-drug therapy or suppression of emergence resistance. RNA transcription was not greatly altered by the addition of rifampicin, which may be due to strong transcriptional influence of azithromycin and host cells. This questions the role of rifampicin in the currently recommended therapy. These findings should be confirmed in clinical trials.

References Powered by Scopus

Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2

54485Citations
N/AReaders
Get full text

STAR: Ultrafast universal RNA-seq aligner

29794Citations
N/AReaders
Get full text

Epidemiology of human pulmonary infection with nontuberculous mycobacteria a review

685Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease

17Citations
N/AReaders
Get full text

Drugs for treating infections caused by non-tubercular mycobacteria: a narrative review from the study group on mycobacteria of the Italian Society of Infectious Diseases and Tropical Medicine

10Citations
N/AReaders
Get full text

Rifampicin has no role in treatment of Mycobacterium avium complex pulmonary disease and bactericidal sterilising drugs are needed: a viewpoint

9Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Schildkraut, J. A., Raaijmakers, J., Aarnoutse, R., Hoefsloot, W., Wertheim, H. F. L., & van Ingen, J. (2023). The role of rifampicin within the treatment of Mycobacterium avium pulmonary disease. Antimicrobial Agents and Chemotherapy, 67(11). https://doi.org/10.1128/aac.00874-23

Readers' Seniority

Tooltip

Professor / Associate Prof. 3

38%

PhD / Post grad / Masters / Doc 3

38%

Researcher 2

25%

Readers' Discipline

Tooltip

Medicine and Dentistry 8

73%

Agricultural and Biological Sciences 2

18%

Pharmacology, Toxicology and Pharmaceut... 1

9%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 10

Save time finding and organizing research with Mendeley

Sign up for free